Clinical Trial Update: Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing intravitreal bevacizumab to sham in acute branch retinal vein occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Retinal Disease | Phase 3 | Status: COMPLETED